Pulmonary Arterial Hypertension: MR Imaging-derived First-Pass Bolus Kinetic Parameters Are Biomarkers for Pulmonary Hemodynamics, Cardiac Function, and Ventricular Remodeling

Published Online:https://doi.org/10.1148/radiol.12111001

Pulmonary transit time, left ventricular (LV) full width at half maximum, and LV time to peak are compound markers in the noninvasive evaluation of pulmonary hemodynamics, right ventricular function, and ventricular remodeling in patients with pulmonary arterial hypertension.


To prospectively compare contrast material–enhanced (CE) magnetic resonance (MR) imaging–derived right-to-left ventricle pulmonary transit time (PTT), left ventricular (LV) full width at half maximum (FWHM), and LV time to peak (TTP) between patients with pulmonary arterial hypertension (PAH) and healthy volunteers and to correlate these measurements with survival markers in patients with PAH.

Materials and Methods

This HIPAA-compliant study received institutional review board approval. Written informed consent was obtained from all participants. Forty-three patients (32 with PAH [29 women; median age, 55.4 years], 11 with scleroderma but not PAH [seven women; median age, 58.9 years]) underwent right-sided heart catheterization and 3-T CE cardiac MR imaging. Eighteen age- and sex-matched healthy control subjects (12 women; median age, 51.7 years) underwent only CE MR imaging. A short-axis saturation-recovery gradient-echo section was acquired in the basal third of both ventricles, and right-to-left-ventricle PTT, LV FWHM, and LV TTP were calculated. Statistical analysis included Kruskal-Wallis test, Wilcoxon rank sum test, Spearman correlation coefficient, multiple linear regression analysis, and Lin correlation coefficient analysis.


Patients had significantly longer PTT (median, 8.2 seconds; 25th–75th percentile, 6.9–9.9 seconds), FWHM (median, 8.2 seconds; 25th–75th percentile, 5.7–11.4 seconds), and TTP (median, 4.8 seconds; 25th–75th percentile, 3.9–6.5 seconds) than did control subjects (median, 6.4 seconds; 25th–75th percentile, 5.7–7.1 seconds; median, 5.2 seconds; 25th–75th percentile, 4.1–6.1 seconds; median, 3.2 seconds; 25th–75th percentile, 2.8–3.8 seconds, respectively; P < .01 for each) and subjects with scleroderma but not PAH (median, 6.5 seconds; 25th–75th percentile, 5.6–7.0 seconds; median, 5.0 seconds; 25th–75th percentile, 4.0–7.3 seconds; median, 3.6 seconds; 25th–75th percentile, 2.7–4.0 seconds, respectively; P < .02 for each). PTT, LV FWHM, and LV TTP correlated with pulmonary vascular resistance index (P < .01), right ventricular stroke volume index (P ≤ .01), and pulmonary artery capacitance (P ≤ .02). In multiple linear regression models, PTT, FWHM, and TTP were associated with mean pulmonary arterial pressure and cardiac index.


CE MR-derived PTT, LV FWHM, and LV TTP are noninvasive compound markers of pulmonary hemodynamics and cardiac function in patients with PAH. Their predictive value for patient outcome warrants further investigation.

© RSNA, 2012

Supplemental materialhttp://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12111001/-/DC1


  • 1 McLaughlin VV, Archer SL, Badesch DB, et al.. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association—developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119(16):2250–2294. Crossref, MedlineGoogle Scholar
  • 2 McLaughlin VV, Presberg KW, Doyle RL, et al.. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):78S–92S. Crossref, MedlineGoogle Scholar
  • 3 Campo A, Mathai SC, Le Pavec J, et al.. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182(2):252–260. Crossref, MedlineGoogle Scholar
  • 4 Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009;120(11):992–1007. Crossref, MedlineGoogle Scholar
  • 5 Roeleveld RJ, Marcus JT, Boonstra A, et al.. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. J Magn Reson Imaging 2005;22(1):67–72. Crossref, MedlineGoogle Scholar
  • 6 Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147(2):218–223. Crossref, MedlineGoogle Scholar
  • 7 Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008;52(21):1683–1692. Crossref, MedlineGoogle Scholar
  • 8 Jones RH, Sabiston DC, Bates BB, Morris JJ, Anderson PA, Goodrich JK. Quantitative radionuclide angiocardiography for determination of chamber to chamber cardiac transit times. Am J Cardiol 1972;30(8):855–864. Crossref, MedlineGoogle Scholar
  • 9 Selzer A, Dunlap RW, Wray HW, Russell J. A critical appraisal of the circulation time test. Arch Intern Med 1968;122(6):491–495. Crossref, MedlineGoogle Scholar
  • 10 Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837–1847. Crossref, MedlineGoogle Scholar
  • 11 Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007;356(1):39–46. Crossref, MedlineGoogle Scholar
  • 12 Levin JR, Serlin RC, Seaman MA. Controlled, powerful multi-comparison strategy for several situations. Psychol Bull 1994;115(1):153–159. CrossrefGoogle Scholar
  • 13 Fisher RA. The design of experiments. Edinburgh, Scotland: Oliver & Boyd, 1935. Google Scholar
  • 14 Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45(1):255–268. Crossref, MedlineGoogle Scholar
  • 15 Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121(18):2045–2066. Crossref, MedlineGoogle Scholar
  • 16 Francois CJ, Shors SM, Bonow RO, Finn JP. Analysis of cardiopulmonary transit times at contrast material-enhanced MR imaging in patients with heart disease. Radiology 2003;227(2):447–452. LinkGoogle Scholar
  • 17 Shors SM, Cotts WG, Pavlovic-Surjancev B, François CJ, Gheorghiade M, Finn JP. Heart failure: evaluation of cardiopulmonary transit times with time-resolved MR angiography. Radiology 2003;229(3):743–748. LinkGoogle Scholar
  • 18 Cao JJ, Wang Y, McLaughlin J, et al.. Prolonged pulmonary transit time by cardiac MRI is a marker of hemodynamic derangement in patients with congestive heart failure. J Cardiovasc Magn Reson 2010;12(Suppl 1):P96. Google Scholar
  • 19 Goldman J, Cohen E, Rosenbluth A, Poon M. Contrast bolus MR transit time through the pulmonary circulation in pulmonary hypertension: a novel noninvasive index of pulmonary flow [abstr]. In: Proceedings of the Tenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2002; 403. Google Scholar
  • 20 Lakoma A, Tuite D, Sheehan J, Weale P, Carr JC. Measurement of pulmonary circulation parameters using time-resolved MR angiography in patients after Ross procedure. AJR Am J Roentgenol 2010;194(4):912–919. Crossref, MedlineGoogle Scholar
  • 21 Sergiacomi G, Bolacchi F, Cadioli M, et al.. Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. Radiology 2010;254(2):601–608. LinkGoogle Scholar
  • 22 Voelkel NF, Quaife RA, Leinwand LA, et al.. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006;114(17):1883–1891. Crossref, MedlineGoogle Scholar
  • 23 Condliffe R, Kiely DG, Peacock AJ, et al.. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179(2):151–157. Crossref, MedlineGoogle Scholar
  • 24 Mahapatra S, Nishimura RA, Oh JK, McGoon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 2006;19(8):1045–1050. Crossref, MedlineGoogle Scholar
  • 25 Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006;47(4):799–803. Crossref, MedlineGoogle Scholar
  • 26 Mousseaux E, Tasu JP, Jolivet O, Simonneau G, Bittoun J, Gaux JC. Pulmonary arterial resistance: noninvasive measurement with indexes of pulmonary flow estimated at velocity-encoded MR imaging—preliminary experience. Radiology 1999;212(3):896–902. LinkGoogle Scholar
  • 27 Tardivon AA, Mousseaux E, Brenot F, et al.. Quantification of hemodynamics in primary pulmonary hypertension with magnetic resonance imaging. Am J Respir Crit Care Med 1994;150(4):1075–1080. Crossref, MedlineGoogle Scholar
  • 28 Laffon E, Laurent F, Bernard V, De Boucaud L, Ducassou D, Marthan R. Noninvasive assessment of pulmonary arterial hypertension by MR phase-mapping method. J Appl Physiol 2001;90(6):2197–2202. Crossref, MedlineGoogle Scholar
  • 29 Alunni JP, Degano B, Arnaud C, et al.. Cardiac MRI in pulmonary artery hypertension: correlations between morphological and functional parameters and invasive measurements. Eur Radiol 2010;20(5):1149–1159. Crossref, MedlineGoogle Scholar
  • 30 Frank H, Globits S, Glogar D, Neuhold A, Kneussl M, Mlczoch J. Detection and quantification of pulmonary artery hypertension with MR imaging: results in 23 patients. AJR Am J Roentgenol 1993;161(1):27–31. Crossref, MedlineGoogle Scholar
  • 31 Saba TS, Foster J, Cockburn M, Cowan M, Peacock AJ. Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. Eur Respir J 2002;20(6):1519–1524. Crossref, MedlineGoogle Scholar
  • 32 Vogel-Claussen J, Shehata ML, Lossnitzer D, Skrok J, Bluemke DA, Hassoun PM. Increased right ventricular septomarginal trabeculation mass is a novel marker for pulmonary hypertension: comparison with ventricular mass index [abstr]. In: Radiological Society of North America scientific assembly and annual meeting program. Oak Brook, Ill: Radiological Society of North America, 2009; 617–618. Google Scholar
  • 33 Ley S, Mereles D, Puderbach M, et al.. Value of MR phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension. Eur Radiol 2007;17(7):1892–1897. Crossref, MedlineGoogle Scholar
  • 34 Kreitner KF, Kunz RP, Weschler C, et al.. Systematic analysis of the geometry of a defined contrast medium bolus: implications for contrast enhanced 3D MR-angiography of thoracic vessels [in German]. Rofo 2005;177(5):646–654. Crossref, MedlineGoogle Scholar
  • 35 Jalandhara N, Arora R, Batuman V. Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update. Clin Pharmacol Ther 2011;89(6):920–923. Crossref, MedlineGoogle Scholar

Article History

Received May 15, 2011; revision requested July 12; revision received October 14; accepted October 20; final version accepted January 6, 2012.
Published online: June 2012
Published in print: June 2012